{"id":3940,"date":"2023-10-18T11:36:01","date_gmt":"2023-10-18T15:36:01","guid":{"rendered":"https:\/\/site1713356525.mywhc.ca\/projets-finances\/vulnerability-therapeutics-in-leukemia-acute-emc2\/"},"modified":"2023-11-22T13:41:56","modified_gmt":"2023-11-22T18:41:56","slug":"vulnerability-therapeutics-in-leukemia-acute-emc2","status":"publish","type":"funded-project","link":"https:\/\/oncopole.ca\/en\/funded-project\/vulnerability-therapeutics-in-leukemia-acute-emc2\/","title":{"rendered":"Therapeutic vulnerability in acute leukemia &#8211; EMC2"},"content":{"rendered":"<p><iframe title=\"Combattre les r\u00e9cidives dans les leuc\u00e9mies gr\u00e2ce aux cellules souches- Concours EMC\u00b2\" width=\"800\" height=\"450\" src=\"https:\/\/www.youtube.com\/embed\/W3XoYGgukLM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" allowfullscreen><\/iframe><\/p>\n<p>Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and ALL-T accounts for 20% of these cancers, peaking at 2-5 years of age. Although this cancer originates in the thymus, it spreads throughout the body and is rapidly lethal without treatment. Current treatments for T-ALL achieve good survival rates of 90% in children, but with serious side effects that impair their long-term quality of life. What&#8217;s more, around 50% of adolescents and 60% of adults succumb to T-ALL. In contrast, acute myeloblastic leukemia is more common in adults with a low long-term survival rate, despite intensive high-dose chemotherapy.<\/p>\n<p>The team has previously shown that leukemic stem cells that are spared by current treatment actually depend on their interactions with a niche for survival, revealing a vulnerability that they propose to exploit in order to develop new compounds that prevent this critical interaction. The project involves a multidisciplinary team of researchers working in synergy from bench to bedside at three universities: IRIC-Universit\u00e9 de Montr\u00e9al, MUHC and Universit\u00e9 de Sherbrooke, as well as CHU Sainte-Justine.<\/p>\n","protected":false},"author":1,"parent":0,"template":"","meta":{"_acf_changed":false},"concour":[58],"class_list":["post-3940","funded-project","type-funded-project","status-publish","hentry","concour-emc2-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/funded-project\/3940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/funded-project"}],"about":[{"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/types\/funded-project"}],"author":[{"embeddable":true,"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:attachment":[{"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/media?parent=3940"}],"wp:term":[{"taxonomy":"concour","embeddable":true,"href":"https:\/\/oncopole.ca\/en\/wp-json\/wp\/v2\/concour?post=3940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}